Fusion protein clears amyloid-β
IN BRIEF
02 September 2022
A challenge facing amyloid-β (Aβ)-targeted approaches for Alzheimer disease (AD) is to avoid the neurotoxic pro-inflammatory side effects associated with conventional antibodies. Jung et al. harness the phagocytic and anti-inflammatory activity of GAS6-mediated TAM receptor activation by developing a fusion protein, αAβ–GAS6, comprised of a single-chain variable fragment of aducanumab fused with the receptor-binding domain of GAS6. In mouse models of AD, αAβ–GAS6 enhanced microglia- and astrocyte-mediated Aβ phagocytosis and suppressed inflammation, leading to improved cognitive functions, reduced synapse elimination and decreased microhaemorrhage compared with aducanumab treatment.
Access options
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
Additional access options:
doi: https://doi.org/10.1038/d41573-022-00150-x
Jobs
留言 (0)